Literature DB >> 14694036

Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS.

C Malmeström1, S Haghighi, L Rosengren, O Andersen, J Lycke.   

Abstract

OBJECTIVE: To determine if CNS-derived proteins present in the CSF of multiple sclerosis (MS) patients reflect different pathologic processes of MS and if these proteins could be useful as biologic markers of disease activity.
METHODS: Concentrations of the neurofilament light protein (NFL), glial fibrillary acidic protein (GFAP), S100B, and the neuron-specific enolase protein (NSE) were determined in the CSF of 66 MS patients and 50 healthy control subjects with immunoassays.
RESULTS: The mean levels of the NFL were increased during all stages of MS compared with controls (p < 0.001), peaking almost 10 times higher during acute relapses. The highest levels of GFAP were found during the secondary progressive course (p < 0.001) with a strong correlation with neurologic deficits (Expanded Disability Status Scale score, r = 0.73, p < 0.001). No increase of S100B or NSE protein was found in the CSF of MS patients compared with control subjects.
CONCLUSIONS: Increased level of NFL is a general feature of MS, indicating continuous axonal damage during the entire course of the disease with the most profound damage during acute relapses. GFAP may serve as a biomarker for disease progression, probably reflecting the increasing rate of astrogliosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14694036     DOI: 10.1212/01.wnl.0000098880.19793.b6

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  90 in total

Review 1.  Early-stage multiple sclerosis : what are the treatment options?

Authors:  Per Soelberg Sorensen
Journal:  Drugs       Date:  2004       Impact factor: 9.546

2.  Upregulation of astrocytic leptin receptor in mice with experimental autoimmune encephalomyelitis.

Authors:  Xiaojun Wu; Hung Hsuchou; Abba J Kastin; Pramod K Mishra; Weihong Pan
Journal:  J Mol Neurosci       Date:  2012-06-10       Impact factor: 3.444

3.  Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis.

Authors:  Ales Bartos; Lenka Fialová; Jirina Soukupová; Jaromír Kukal; Ivan Malbohan; Jirí Pit'ha
Journal:  J Neurol       Date:  2007-02-14       Impact factor: 4.849

4.  Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis.

Authors:  K Rejdak; A Petzold; T Kocki; J Kurzepa; P Grieb; W A Turski; Z Stelmasiak
Journal:  J Neural Transm (Vienna)       Date:  2007-03-29       Impact factor: 3.575

Review 5.  Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported.

Authors:  Axel Petzold; Gordon T Plant
Journal:  J Neurol       Date:  2013-05-23       Impact factor: 4.849

Review 6.  A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition.

Authors:  Hernan Inojosa; Undine Proschmann; Katja Akgün; Tjalf Ziemssen
Journal:  J Neurol       Date:  2019-07-30       Impact factor: 4.849

7.  Naturally presented peptides on major histocompatibility complex I and II molecules eluted from central nervous system of multiple sclerosis patients.

Authors:  Nicolas Fissolo; Sabrina Haag; Katrien L de Graaf; Oliver Drews; Stefan Stevanovic; Hans Georg Rammensee; Robert Weissert
Journal:  Mol Cell Proteomics       Date:  2009-06-16       Impact factor: 5.911

Review 8.  Secondary Progressive Multiple Sclerosis: Definition and Measurement.

Authors:  Domenico Plantone; Floriana De Angelis; Anisha Doshi; Jeremy Chataway
Journal:  CNS Drugs       Date:  2016-06       Impact factor: 5.749

9.  Brain antigens in functionally distinct antigen-presenting cell populations in cervical lymph nodes in MS and EAE.

Authors:  Marloes van Zwam; Ruth Huizinga; Marie-José Melief; Annet F Wierenga-Wolf; Marjan van Meurs; Jane S Voerman; Knut P H Biber; Hendrikus W G M Boddeke; Uta E Höpken; Christian Meisel; Andreas Meisel; Ingo Bechmann; Rogier Q Hintzen; Bert A 't Hart; Sandra Amor; Jon D Laman; Leonie A Boven
Journal:  J Mol Med (Berl)       Date:  2008-12-03       Impact factor: 4.599

10.  Cerebrospinal fluid in multiple sclerosis.

Authors:  Kottil W Rammohan
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.